Organoidsciences Ltd. (KOSDAQ:476040)

Market Cap	194.67B
Revenue (ttm)	1.95B
Net Income (ttm)	-11.25B
Shares Out	6.55M
EPS (ttm)	-2,690.83
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	142,092
Average Volume	353,109
Open	30,450
Previous Close	30,300
Day's Range	29,000 - 30,950
52-Week Range	21,000 - 52,000
Beta	n/a
RSI	41.09
Earnings Date	n/a

About Organoidsciences

Organoidsciences Ltd. develops regenerative therapies in South Korea. It develops ATORM, an adult tissue derived organoid based regenerative medicine platform for the treatment of intractable intestinal ulcers, as well as salivary glands, liver, and uterus disease areas; ODISEI solutions, an organoid-based discovery platform for screening evaluation and identification; and EXPANSION, an organoid-based advanced science for innovative solutions. The company was founded in 2018 and is based in Seongnam-si, South Korea.

• Industry: Pharmaceutical Preparations
• Founded: 2018
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 476040

Financial Performance

In 2024, Organoidsciences's revenue was 1.95 billion, an increase of 22.77% compared to the previous year's 1.59 billion. Losses were -11.25 billion, -70.93% less than in 2023.